Loading...
XSTO
AXIC A
Market cap16mUSD
May 23, Last price  
2.60SEK
1D
-9.09%
1Q
92.59%
Jan 2017
-50.94%
IPO
-76.86%
Name

aXichem AB (publ)

Chart & Performance

D1W1MN
P/E
—
P/S
17.93
EPS
—
Div Yield, %
—
Shrs. gr., 5y
22.86%
Rev. gr., 5y
90.34%
Revenues
9m
+373.74%
000000376,000000344,000343,0001,227,0004,362,0005,007,0001,809,0008,570,000
Net income
-18m
L-14.41%
-1,048,343-1,714,510-2,373,899-2,357,067-3,483,130-3,656,563-5,628,000-7,423,000-6,072,000-7,375,000-9,927,000-12,678,000-13,515,000-15,093,000-17,260,000-20,811,000-17,813,000
CFO
-12m
L-26.62%
7,417,083-2,998,397-1,131,528-428,503-4,885,777-4,293,957-9,014,000-7,977,000-5,526,000-7,688,000-7,461,000-12,294,000-11,694,000-15,595,000-19,098,000-15,677,000-11,503,000

Profile

aXichem AB, a biotechnology company, engages in the development of natural analogue ingredients in Sweden. It offers aXivite, an natural analogue capsaicin solution for a range of dietary health applications; aXiphen-bio, a bio-repellent for antifouling protection for vessels and marine installations, pest control in agriculture and forestry, and pest control for cable installations in buildings and underground cables; and aXiphen-feed, a solution for enhanced health for chickens, hens, pigs, and piglets. The company was incorporated in 2007 and is based in Malmö, Sweden.
URL
https://www.axichem.se/
IPO date
Jul 10, 2008
Employees
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
8,570
373.74%
1,809
-63.87%
5,007
14.79%
Cost of revenue
1,489
2,019
2,592
Unusual Expense (Income)
NOPBT
7,081
(210)
2,415
NOPBT Margin
82.63%
48.23%
Operating Taxes
32
25
25
Tax Rate
0.45%
1.04%
NOPAT
7,049
(235)
2,390
Net income
(17,813)
-14.41%
(20,811)
20.57%
(17,260)
14.36%
Dividends
Dividend yield
Proceeds from repurchase of equity
28,543
BB yield
-34.02%
Debt
Debt current
10,268
18,758
Long-term debt
Deferred revenue
Other long-term liabilities
19,556
Net debt
(14,359)
5,959
12,209
Cash flow
Cash from operating activities
(11,503)
(15,677)
(19,098)
CAPEX
(2,608)
Cash from investing activities
(6,499)
(5,103)
(2,608)
Cash from financing activities
28,053
18,543
18,800
FCF
7,999
(1,216)
(2,816)
Balance
Cash
14,359
4,309
6,549
Long term investments
Excess cash
13,930
4,219
6,299
Stockholders' equity
(136,291)
(125,995)
(13,929)
Invested Capital
206,449
184,790
72,989
ROIC
3.60%
3.38%
ROCE
10.09%
4.09%
EV
Common stock shares outstanding
46,093
20,924
17,187
Price
1.36
-66.08%
4.01
-71.05%
13.85
-43.70%
Market cap
62,687
-25.29%
83,904
-64.75%
238,035
-43.01%
EV
48,352
89,885
359,749
EBITDA
7,081
3,624
5,926
EV/EBITDA
6.83
24.80
60.71
Interest
1,956
3,471
2,690
Interest/NOPBT
27.62%
111.39%